Evidence map›Paper›PMID 39817651›Full record

ReviewThe Kaohsiung journal of medical sciences2025

Antithrombotic use in retinal artery occlusion: A narrative review.

Wan-Yu Liu, Yun-Hsin Tang, Yi-Hsing Chen

Abstract readReview
In one paragraph

Review in The Kaohsiung journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Antithrombotic use in retinal artery occlusion: A narrative review.The Kaohsiung journal of medical sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Wan-Yu LiuDepartment of Medical Education, Chang Gung Memorial Hospital, Linkou Main Branch, Taoyuan, Taiwan.
Yun-Hsin TangDepartment of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Linkou Main Branch, Taoyuan, Taiwan.
Yi-Hsing ChenCollege of Medicine, Chang Gung University, Taoyuan, Taiwan.ORCID https://orcid.org/0000-0002-2682-939X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retinal artery occlusion (RAO) is a critical ophthalmic emergency with a high risk of significant visual impairment. While traditional treatment aims to promptly restore blood flow to the retina, recent research has investigated the potential benefits of anticoagulation therapy for managing this condition. This paper reviews current literature and clinical trials investigating the efficacy and safety of anticoagulant and antiplatelet therapies, such as systemic heparinization and direct oral anticoagulants and aspirin, in treating RAO. The mechanism of action involves preventing thrombus propagation and platelet aggregation to promote microvascular circulation, potentially mitigating ischemic damage and improving visual outcomes. However, controversies exist regarding the optimal timing, duration, and selection of antithrombotic agents due to the risk of hemorrhagic complications. Further large-scale prospective studies are warranted to establish evidence-based guidelines for incorporating antithrombotic into the standard management of RAO. This paper underscores the evolving landscape of antithrombotic therapy as a promising adjunctive treatment strategy in the management of retinal artery occlusion.

Indexed as

AnticoagulantsFibrinolytic AgentsRetinal Artery OcclusionAspirinHumansPlatelet Aggregation InhibitorsAnticoagulantsAspirinFibrinolytic AgentsPlatelet Aggregation Inhibitorsanticoagulant therapyantiplatelet therapyretinal artery occlusion

Identifiers

PMID39817651
PMCPMC11964108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.